P4O2: A study for people with lung scarring
Part of Lungs & breathing clinical trials.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung scarring, such as idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis, or other fibrotic lung disease.
- Your lung function tests meet certain levels: FVC (breathing capacity) is at least 45% of normal, and DLco (oxygen uptake) is at least 40% of normal.
- You are between 18 and 80 years old.
- You can understand and speak Dutch or English.
- You do not have combined scarring and emphysema (CPFE), active cancer (except minor skin, breast, or prostate cancers), or severe asthma/COPD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.